This fact sheet reviews some potential barriers that older adults face when accessing generic drugs, the lower-cost versions of brand-name drugs that enter the market after a brand-name drug’s monopoly period ends.
The fact sheets in this series offer data for each of the 11 states that have not yet expanded Medicaid, including the number of people who would be eligible under expansion, their demographic characteristics, what kind of insurance they currently have, the likelihood they would enroll in Medicaid, and the potential cost savings for each state’s budget.
Standardized, consumer-centered improvements to the style, organization and content of prescription drug container labels may help consumers manage their medications and, importantly, reduce medication errors.
Consumers facing high costs for prescription drugs can see substantial savings when they switch from a brand-name drug to a generic equivalent, but this option is not yet widely available for biologic drugs. This fact sheet examines biosimilar substitution laws in each state that may be affecting consumer access.
This Fact Sheet examines the prevalence of influenza, pneumonia, and shingles vaccinations among adults ages 50 and older in 2020. Vaccinations for all three diseases increased from 2019, yet racial and ethnic disparities continue.
This Fact Sheet examines prescription drug utilization management (UM) among the top 10 marketplace plans in all 50 states and the District of Columbia and finds considerable variation among states in UM for prescription drugs commonly used by adults 50 to 64.
A series of three AARP Public Policy Institute and Mathematica Spotlight reports analyze SNAP participation among older adults and the policies that affect it.
